X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5077) 5077
Book Review (1051) 1051
Publication (238) 238
Magazine Article (22) 22
Book Chapter (17) 17
Conference Proceeding (17) 17
Book / eBook (11) 11
Dissertation (6) 6
Reference (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4767) 4767
humans (4022) 4022
male (2961) 2961
parkinson disease - drug therapy (2940) 2940
antiparkinson agents - therapeutic use (2428) 2428
parkinson's disease (2406) 2406
female (2314) 2314
clinical neurology (1939) 1939
antiparkinson agents - administration & dosage (1920) 1920
middle aged (1918) 1918
aged (1856) 1856
antiparkinson agents - adverse effects (1593) 1593
animals (1557) 1557
neurosciences (1410) 1410
levodopa - therapeutic use (1319) 1319
levodopa (1159) 1159
levodopa - administration & dosage (1155) 1155
antiparkinson agents - pharmacology (1058) 1058
levodopa - adverse effects (986) 986
pharmacology & pharmacy (935) 935
parkinson disease - physiopathology (872) 872
adult (812) 812
rats (747) 747
treatment outcome (690) 690
dose-response relationship, drug (668) 668
parkinsons-disease (643) 643
dopamine (640) 640
l-dopa (592) 592
drug therapy, combination (581) 581
dopa (563) 563
neurology (535) 535
parkinson disease - complications (477) 477
motor fluctuations (466) 466
disease models, animal (459) 459
time factors (448) 448
double-blind (445) 445
levodopa - pharmacology (439) 439
abridged index medicus (423) 423
antiparkinson agents - pharmacokinetics (417) 417
parkinsons disease (402) 402
aged, 80 and over (396) 396
drug administration schedule (388) 388
basal ganglia (385) 385
psychiatry (369) 369
dopamine - metabolism (367) 367
double-blind method (366) 366
severity of illness index (361) 361
drug combinations (360) 360
dyskinesia (357) 357
analysis (349) 349
motor activity - drug effects (349) 349
rats, sprague-dawley (347) 347
parkinson disease - therapy (343) 343
parkinsonian disorders - drug therapy (338) 338
carbidopa - administration & dosage (333) 333
movement disorders (321) 321
disease (300) 300
drug therapy (300) 300
parkinson disease - metabolism (300) 300
mice (299) 299
therapy (282) 282
parkinson disease - diagnosis (281) 281
parkinson disease - psychology (279) 279
dyskinesia, drug-induced - etiology (274) 274
dopamine agonists - therapeutic use (273) 273
pharmacokinetics (251) 251
levodopa - pharmacokinetics (249) 249
brain (244) 244
dopamine agonists - administration & dosage (244) 244
care and treatment (236) 236
corpus striatum - drug effects (235) 235
apomorphine (234) 234
parkinson disease (231) 231
subthalamic nucleus (231) 231
dyskinesia, drug-induced - drug therapy (229) 229
carbidopa - therapeutic use (228) 228
administration, oral (224) 224
follow-up studies (222) 222
research (221) 221
corpus striatum - metabolism (219) 219
neurons (218) 218
deep brain stimulation (214) 214
brain - drug effects (212) 212
rats, wistar (202) 202
dopamine agonists - adverse effects (199) 199
antiparkinsonian agents (196) 196
quality of life (195) 195
substantia-nigra (195) 195
analysis of variance (192) 192
phenols (192) 192
drug interactions (191) 191
behavior, animal - drug effects (186) 186
risk factors (184) 184
dyskinesias (181) 181
clinical trials as topic (180) 180
neurodegenerative diseases (180) 180
apomorphine - administration & dosage (177) 177
brain - metabolism (177) 177
disease progression (177) 177
retrospective studies (177) 177
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4713) 4713
German (75) 75
Japanese (71) 71
Russian (70) 70
Spanish (52) 52
French (42) 42
Hungarian (22) 22
Polish (21) 21
Dutch (12) 12
Danish (8) 8
Italian (6) 6
Swedish (6) 6
Norwegian (5) 5
Hebrew (4) 4
Chinese (3) 3
Finnish (2) 2
Romanian (2) 2
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 06/2015, Volume 207, pp. 18 - 30
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as drug delivery vehicles in the past few years. Exosomes are... 
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | ALZHEIMERS-DISEASE | REPEATED INJECTIONS | MACROPHAGE DELIVERY | MEDIATED TRANSFER | BLOOD-BRAIN-BARRIER | BIOLOGICAL BARRIERS | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PEGYLATED LIPOSOMES | PHARMACOLOGY & PHARMACY | SUPEROXIDE-DISMUTASE | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles | Index Medicus
Journal Article
Annals of Neurology, ISSN 0364-5134, 07/2010, Volume 68, Issue 1, pp. 18 - 27
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 06/2013, Volume 123, Issue 6, pp. 2730 - 2736
Journal Article
Science, ISSN 0036-8075, 11/2007, Volume 318, Issue 5854, pp. 1309 - 1312
Deep brain stimulation (DBS) of the subthalamic nucleus markedly improves the motor symptoms of Parkinson's disease, but causes cognitive side effects such as... 
Neurology | Basal ganglia | Health outcomes | Deep brain stimulation | Parkinson disease | Medications | Thalamus | Reports | Lesions | Behavioral neuroscience | Modeling | CHOICE | SUBTHALAMIC NUCLEUS | REACTION-TIME | OPTIMAL DECISION-MAKING | BASAL GANGLIA | MULTIDISCIPLINARY SCIENCES | DISEASE | DOPAMINE | HIGH-FREQUENCY STIMULATION | COGNITIVE CONTROL | SELECTION | Parkinson Disease - therapy | Impulsive Behavior - etiology | Humans | Middle Aged | Male | Reaction Time | Deep Brain Stimulation - adverse effects | Dopamine Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Dopamine Agents - adverse effects | Learning | Levodopa - administration & dosage | Conflict (Psychology) | Female | Dopamine Agents - administration & dosage | Neural Networks (Computer) | Decision Making | Levodopa - therapeutic use | Reinforcement (Psychology) | Parkinson Disease - physiopathology | Parkinson Disease - psychology | Antiparkinson Agents - adverse effects | Basal Ganglia - physiology | Subthalamic Nucleus - physiology | Levodopa - adverse effects | Aged | Antiparkinson Agents - administration & dosage | Models, Neurological | Parkinsonism | Psychological aspects | Physiological aspects | Brain stimulation | Impulse | Health aspects | Brain | Side effects | Cognition & reasoning | Medical treatment | Parkinsons disease | Drug therapy | Index Medicus
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2016, Volume 15, Issue 2, pp. 154 - 165
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9923, pp. 1138 - 1146
Journal Article
Movement Disorders, ISSN 0885-3185, 05/2015, Volume 30, Issue 6, pp. 788 - 795
Journal Article
Journal Article
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 02/2013, Volume 48, Issue 3, pp. 393 - 405
Graphical abstract showing biodistribution studies on organ of interest of different formulations administered by different routes (a) bromocriptine (BRC)... 
Nanoparticles | Parkinson disease | Chitosan | Haloperidol | Bromocriptine | Biodistribution study | SYSTEM | DRUG-DELIVERY | TARGETING EFFICIENCY | INTRANASAL DELIVERY | FORMULATION | IN-VIVO | PHARMACOLOGY & PHARMACY | OLANZAPINE | PLGA NANOPARTICLES | PARKINSONS-DISEASE | BLOOD | Catalepsy - etiology | Brain - diagnostic imaging | Bromocriptine - administration & dosage | Injections, Intravenous | Nanoparticles - chemistry | Catalepsy - prevention & control | Male | Parkinson Disease - drug therapy | Hypokinesia - etiology | Bromocriptine - metabolism | Bromocriptine - therapeutic use | Drug Delivery Systems | Antiparkinson Agents - therapeutic use | Brain - metabolism | Tissue Distribution | Sodium Pertechnetate Tc 99m | Bromocriptine - pharmacokinetics | Drug Compounding | Behavior, Animal - drug effects | Neurons - metabolism | Parkinson Disease - metabolism | Neurons - drug effects | Disease Models, Animal | Hypokinesia - prevention & control | Parkinson Disease - diagnostic imaging | Random Allocation | Parkinson Disease - physiopathology | Administration, Intranasal | Blood-Brain Barrier - drug effects | Antiparkinson Agents - pharmacokinetics | Brain - drug effects | Neurons - diagnostic imaging | Animals | Chitosan - chemistry | Radionuclide Imaging | Antiparkinson Agents - administration & dosage | Mice | Antiparkinson Agents - metabolism | Brain | Central nervous system depressants | Index Medicus
Journal Article
CLINICAL INTERVENTIONS IN AGING, ISSN 1176-9092, 2010, Volume 5, pp. 229 - 238
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson's disease (PD).... 
Parkinson's disease | levodopa | motor fluctuations | dyskinesia | GERIATRICS & GERONTOLOGY | Dyskinesia, Drug-Induced - etiology | Levodopa - administration & dosage | Humans | Levodopa - adverse effects | Aged | Antiparkinson Agents - administration & dosage | Parkinson Disease - drug therapy | Antiparkinson Agents - adverse effects
Journal Article